Products & Services · R&D
INS1148 — R&D
Insmed INS1148 — R&D remained flat by 0.0% to $10.00M in Q4 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2025
Rolls up toR&D
How to read this metric
An increase typically signals accelerated clinical development or preparation for regulatory milestones, while a decrease may indicate the completion of a development phase or a strategic shift in pipeline prioritization.
Detailed definition
This metric represents the direct operating expenses allocated to the research and development activities specifically a...
Peer comparison
Comparable to R&D expenses for specific clinical-stage drug candidates at other biopharmaceutical companies, often benchmarked against phase-specific development costs.
Metric ID:
insm_segment_ins1148_research_and_developmentHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.00 | $0.00 | $40.00M |
Range$0.00 – $40.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's ins1148 — r&d?
- Insmed (INSM) reported ins1148 — r&d of $10.00M in Q4 2025.
- What does ins1148 — r&d mean?
- The total costs incurred to research and develop the specific INS1148 therapeutic candidate.